Chronic lymphocytic leukaemia (CLL) treatment is evolving with a focus on limited duration therapies.

Promising combinations like BCL2 inhibitor venetoclax with obinutuzumab are being explored.

New strategies are moving away from traditional chemo immunotherapy towards innovative doublets and triplets. Emerging therapies, including BTK degraders and CAR T-cell treatments, aim to personalise care based on minimal residual disease assessments, ultimately enhancing patient outcomes.